Cours suspendu

Communiqués YMAS THER

Actions

YMAB

US9842411095

Marché Fermé - NYSE Autres places de cotation 22:00:00 15/09/2025			Varia. 5j.	Varia. 1 janv.
8,610 ^USD	+0,23%		-.--%	-

16/09/25	Y-mAbs Therapeutics, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI
16/09/25	Démission de Michael Rossi, Directeur Général de Y-mAbs Therapeutics, Inc., effective au 16 septembre 2025	CI

Communiqués

08/08/25	Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments	AQ
07/08/25	Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB	BU
07/08/25	Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025	AQ
05/08/25	SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics	AQ
24/07/25	Y mAbs Therapeutics : Corporate Presentation (e16b6d)	PU
29/05/25	Y mAbs Therapeutics : YMAB Radiopharma R&D Update Presentation (77158c)	PU
28/05/25	Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline	AQ
26/05/25	Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting	AQ
13/05/25	Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025	AQ
13/05/25	Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments	AQ
13/05/25	Y mAbs Therapeutics : Presentation (a0455d)	PU
07/05/25	Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)	AQ
06/05/25	Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025	AQ
27/04/25	Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting	AQ
25/04/25	Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma	AQ
04/03/25	Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments	AQ
03/03/25	Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications	AQ
20/02/25	Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025	AQ
07/02/25	Y-mAbs to Present at the Oppenheimer 35th Annual Life Sciences Conference	AQ
06/02/25	Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference	AQ
31/01/25	Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting	AQ
13/01/25	Y mAbs Therapeutics : Company Presentation - January	PU
10/01/25	Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities	AQ
10/01/25	Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit	AQ
10/01/25	Y-mAbs Provides Strategic Business Update and 2025 Priorities	AQ